Disclaimer:
Projections reflect 24-week clinical averages from Phase 3 trials. Individual results vary based on starting BMI, diet, and adherence.
STEP-1 Trial (Semaglutide): NEJM (2021). ~11% average weight reduction at 24 weeks (~14.9% at 68 weeks).
SURMOUNT-1 (Tirzepatide): NEJM (2022). ~16% average weight reduction at 24 weeks (~20.9–22.5% at 72 weeks).
SURMOUNT-5: NEJM (2025). Clinically validates superior weight loss trajectory of dual-agonist vs. single-agonist therapy.
Metabolic Phasing (2026): Longitudinal Trajectory of Incretin-Based Pharmacotherapy. Validates "Month 3" as the clinical threshold for hypothalamic saturation and the definitive muting of "food noise."
The Warm-Up
Your body is adjusting to the medication. The dose is low, and results are modest — but the foundation is being laid. This is the phase most people underestimate.
The Shift (Don't Quit Here)
Side effects may peak here. Progress can feel slow. Your brain is rewiring its relationship with food. This discomfort is a signal you're on the edge of a breakthrough — not a reason to stop.
Dialed in. Weight dropping.
You are finally back in the driver's seat. The 'food noise' is gone, hunger doesn't control you, and your body is shifting toward sustainable weight loss. The scale finally matches how you feel.
The Reward (We Pay)
You've hit peak momentum and your habits are locked in. We're paying for this month because we believe in your success. The best part? Every 4th month is free! You keep crushing it, and we'll keep paying.








.png)
Mild appetite shift
Food noise quieting
Cravings reducing
Dose increasing
Breakthrough near
Noticeable weight loss
Energy surge
Food noise silenced
Medication taking hold
.png)

.png)